IDEXX Laboratories Q3 2026: EPS Beats by 8%, Guidance Raised
As seen on the 24/7 Wall St. homepage on November 2, 2026.
Management raised full-year EPS guidance to $14.96-$15.16, and the premium instrument installed base keeps that recurring diagnostics revenue compounding.
Continue ReadingShow less
IDEXX Laboratories posted Q3 2026 GAAP EPS of $4.01, beating expectations and extending its streak of beating consensus EPS to seven consecutive quarters.
CAG Diagnostics recurring revenue drove the quarter, rising 11% on both a reported and organic basis, with international growth outpacing the U.S.
Management raised full-year 2026 EPS guidance to a range of $14.96 to $15.16, lifting revenue guidance as well after acquiring CoVet, an AI clinical assistant for veterinary teams.
Sponsored
IDEXX Cancer Dx is expanding to a multi-cancer panel and inVue Dx keeps adding placements, while operating margin expanded 100 basis points to 33.1% on volume gains, productivity initiatives, and net price realization.
Free cash flow reached $420.8 million, up 13.35% year over year, giving the company room to keep repurchasing shares.
Mentioned: IDXX